{"id":2419,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2020-07-10","marketCap":324.1668395996094,"name":"Poseida Therapeutics Inc","phone":"18587793100","outstanding":95.62000274658203,"symbol":"PSTX","website":"https://poseida.com/","industry":"Biotechnology"},"price":3.31,"year":2023,"month":12,"day":19,"weekday":"Tuesday","title":"Benefits and Drawbacks of holding Poseida Therapeutics Inc stock for the long term","date":"2023-12-19","url":"/posts/2023/12/19/PSTX","content":[{"section":"Benefits:","text":"1. Growth potential: Poseida Therapeutics is focused on developing innovative gene and cell therapies, which have the potential to revolutionize the treatment of various diseases. If successful, the company could experience significant growth in the long term."},{"section":"Benefits:","text":"2. Pipeline of candidates: Poseida Therapeutics has a robust pipeline of candidates, targeting multiple diseases such as cancer, autoimmune disorders, and genetic diseases. This diversification reduces the risk associated with relying on a single drug or therapy."},{"section":"Benefits:","text":"3. Collaborations and partnerships: The company has established collaborations with renowned organizations such as Novartis and Janssen Pharmaceuticals, which provide access to resources, expertise, and additional funding. These partnerships enhance the company's chances of success."},{"section":"Drawbacks:","text":"1. Clinical trial risks: Poseida Therapeutics' success depends on the outcome of its clinical trials. There is always a risk of failure or delays in drug development, which could impact the stock price negatively."},{"section":"Drawbacks:","text":"2. Regulatory challenges: The biotechnology industry is highly regulated, and obtaining necessary approvals for new therapies can be a lengthy and costly process. Delays in regulatory approvals can negatively affect the stock's performance."},{"section":"Drawbacks:","text":"3. Competition: The biotech industry is highly competitive, with many companies vying for market share and breakthrough therapies. Poseida Therapeutics faces competition from both established players and emerging biotech firms, which could impact its market position and stock performance."},{"section":"Conclusion:","text":"Investing in Poseida Therapeutics Inc stock for the long term comes with potential benefits, such as growth opportunities, a robust pipeline, and valuable collaborations. However, investors should also be aware of the risks associated with clinical trials, regulatory challenges, and competition. It is important to conduct thorough research and carefully assess the company's progress before making any investment decisions."}],"tags":["CrossOver55","Long","Biotechnology"],"news":[{"category":"company","date":1702740218,"headline":"Poseida Therapeutics (PSTX) Price Target Increased by 14.29% to 14.28","id":124551316,"image":"","symbol":"PSTX","publisher":"Fintel","summary":"","url":"https://fintel.io/news/poseida-therapeutics-pstx-price-target-increased-by-1429-to-1428-286"},{"category":"company","date":1702366860,"headline":"PSTX, MRKR and GPRO among pre-market losers","id":124461510,"image":"","symbol":"PSTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3253187162"},{"category":"company","date":1702289822,"headline":"Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment","id":124436475,"image":"","symbol":"PSTX","publisher":"Finnhub","summary":"By Sabela Ojea Shares of Poseida Therapeutics on Monday climbed after the company said it received positive early results from the phase 1 trial for a blood cancer treatment. At 9:43 a.m....","url":"https://finnhub.io/api/news?id=35e1141121c845c685c934d8d4ce169afa33200e99c3de4613b6155b88a83bcc"},{"category":"company","date":1702285320,"headline":"Veru, Kodiak Sciences among healthcare movers","id":124437839,"image":"","symbol":"PSTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251426479"},{"category":"company","date":1702280220,"headline":"Poseida Therapeutics price target raised to $10 from $8 at Piper Sandler","id":124441602,"image":"","symbol":"PSTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251322310"},{"category":"company","date":1702278660,"headline":"12 Health Care Stocks Moving In Monday's Pre-Market Session","id":124437608,"image":"","symbol":"PSTX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251293256"},{"category":"company","date":1702277160,"headline":"Piper Sandler Sticks to Their Buy Rating for Poseida Therapeutics (PSTX)","id":124441604,"image":"","symbol":"PSTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251268844"},{"category":"company","date":1702276680,"headline":"Poseida Therapeutics: Strong Buy on Promising CAR-T Therapy and Strategic Roche Partnership","id":124470258,"image":"","symbol":"PSTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3252291793"},{"category":"company","date":1702276260,"headline":"Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday","id":124437249,"image":"","symbol":"PSTX","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251253466"},{"category":"company","date":1702272420,"headline":"Buy Rating on Poseida Therapeutics Amid Promising Clinical Data and Robust Pipeline Potential","id":124441606,"image":"","symbol":"PSTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251196616"},{"category":"company","date":1702272120,"headline":"Poseida Therapeutics price target raised by $5 at H.C. Wainwright, here's why","id":124441607,"image":"","symbol":"PSTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251193380"},{"category":"company","date":1702267920,"headline":"Analysts Offer Insights on Healthcare Companies: Cigna (CI) and Poseida Therapeutics (PSTX)","id":124439349,"image":"","symbol":"PSTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251142168"},{"category":"company","date":1702227600,"headline":"Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting","id":124425935,"image":"https://media.zenfs.com/en/prnewswire.com/4f05f1549db26db37f15a45f2f462010","symbol":"PSTX","publisher":"Yahoo","summary":"Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate. The Company is investigating P-BCMA-ALLO1 in partnership with Roche for the treatment of relapsed/refractory multiple myeloma","url":"https://finance.yahoo.com/news/poseida-therapeutics-presents-positive-early-170000954.html"},{"category":"company","date":1702180440,"headline":"Poseida presents efficacy, safety results from Phase 1 study of P-BCMA-ALLO1","id":124441610,"image":"","symbol":"PSTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3250666842"}]}